Quick Summary

This WHO and HRP guideline is designed to help countries make faster progress, more equitably, on the screening and treatment of cervical cancer. It includes some important shifts in WHO’s recommended approaches to cervical screening, and includes a total of 23 recommendations and 7 good practice statements.

• Among the 23 recommendations, 6 are identical for both the general population of women and for women living with HIV and 12 are different and specific for each population.
• Among the 7 good practice statements, 3 are identical for both the general population of women and for women living with HIV and 2 are different and specific for each population.

Quick Summary

The Enduring Consensus Cervical Cancer Screening and Management Guidelines (Enduring Guidelines) effort is a standing committee of 19 organizations including medical professional societies, patient advocacy groups, and federal agencies, to continuously evaluate new technologies and approaches to cervical cancer screening, management, and surveillance.

In this study, the committee aimed to develop recommendations for dual stain (DS) testing with CINtec PLUS Cytology for use of DS to triage high-risk human papillomavirus (HPV)-positive results. Colposcopy was recommended for individuals testing DS-positive, for triage of positive HPV results from screening with primary HPV testing (with or without genotyping) or with cytology cotesting.

Find out more about the ASCCP Enduring Guideline Process.

National Comprehensive Cancer Network NSCLC and SCLC guideline recommendations for cancer care decision-making

Quick Summary

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) document evidence-based, consensus-driven management to ensure that all patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes.

The NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions to assist in the decision-making process of individuals involved in cancer care (including physicians, nurses, pharmacists, payers, patients and their families), with the ultimate goal of improving patient care and outcomes.

The NCCN Guidelines provide recommendations based on the best evidence available at the time they are derived, and are continuously updated and revised to reflect new data and clinical information that may add to or alter current clinical practice standards.

Read the latest NCCN lung cancer guidelines below:

Quick Summary

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia-Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.

Authors: Masao Omata, Ann-Lii Cheng, Norihiro Kokudo, Masatoshi Kudo, Jeong Min Lee, Jidong Jia, Ryosuke Tateishi, Kwang-Hyub Han, Yoghesh K. Chawla, Shuichiro Shiina, Wasim Jafri, Diana Alcantara Payawal, Takamasa Ohki, Sadahisa Ogasawara, Pei-Jer Chen, Cosmas Rinaldi A. Lesmana, Laurentius A. Lesmana, Rino A. Gani, Shuntaro Obi, A. Kadir Dokmeci, and Shiv Kumar Sarin

Quick Summary

Primary liver cancer, of which around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people.

Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition) in 2018, additional high-quality evidence has emerged with relevance to the diagnosis, staging, and treatment of liver cancer in and outside China. This updated 2019 Edition was written by more than 70 experts in the field of liver cancer in China. They reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years.

Most importantly, the new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People’s Republic of China in December 2019.

Authors: Jian Zhou, Huichuan Sun, Zheng Wang, Wenming Cong, Jianhua Wang, Mengsu Zeng, Weiping Zhou, Ping Bie, Lianxin Liu, Tianfu Wen, Guohong Han, Maoqiang Wang, Ruibao Liu, Ligong Lu, Zhengang Ren, Minshan Chen, Zhaochong Zeng, Ping Liang, Changhong Liang, Min Chen, Fuhua Yan, Wenping Wang, Yuan Ji, Jingping Yun, Dingfang Cai, Yongjun Chen, Wenwu Cheng, Shuqun Cheng, Chaoliu Dai, Wenzhi Guo, Baojin Hua, Xiaowu Huang, Weidong Jia, Yaming Li, Yexiong Li, Jun Liang, Tianshu Liu, Guoyue Lv, Yilei Mao, Tao Peng, Weixin Ren, Hongcheng Shi, Guoming Shi, Kaishan Tao, Wentao Wang, Xiaoying Wang, Zhiming Wang, Bangde Xiang, Baocai Xing, Jianming Xu, Jiamei Yang, Jianyong Yang, Yefa Yang, Yunke Yang, Shenglong Ye, Zhengyu Yin, Bixiang Zhang, Boheng Zhang, Leida Zhang, Shuijun Zhang, Ti Zhang, Yongfu Zhao, Honggang Zheng, Jiye Zhu, Kangshun Zhu, Rong Liu, Yinghong Shi, Yongsheng Xiao, Zhi Dai, Gaojun Teng, Jianqiang Cai, Weilin Wang, Xiujun Cai, Qiang Li, Feng Shen, Shukui Qin, Jiahong Dong, Jia Fan

Quick Summary

The fourth version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine and partly to the Grading of Recommendations Assessment, Development, and Evaluation system, which was published in October 2017 in Japanese. New or revised recommendations were described, herein, with a special reference to the surveillance, diagnostic, and treatment algorithms.

Authors: Norihiro Kokudo, Nobuyuki Takemura, Kiyoshi Hasegawa, Tadatoshi Takayama, Shoji Kubo, Mitsuo Shimada, Hiroaki Nagano, Etsuro Hatano, Namiki Izumi, Shuichi Kaneko, Masatoshi Kudo, Hiroko Iijima, Takuya Genda, Ryosuke Tateishi, Takuji Torimura, Hiroshi Igaki, Satoshi Kobayashi, Hideyuki Sakurai, Takamichi Murakami, Takeyuki Watadani, Yutaka Matsuyama